Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
| Autor: | Bronwyn M. Kivell, Rachel Saylor Crowley, Andrew Biggerstaff, Thomas E. Prisinzano, Sophia Kaska, Kelly F. Paton, Anne C. La Flamme |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Agonist medicine.drug_class Pharmacology Salvinorin A κ-opioid receptor lcsh:RC321-571 Marble burying 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Functional selectivity kappa opioid receptor lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry antinociception Original Research business.industry General Neuroscience anxiety 030104 developmental biology Nociception Anxiogenic chemistry biased agonism Warm water business 030217 neurology & neurosurgery Neuroscience |
| Zdroj: | Frontiers in Neuroscience Frontiers in Neuroscience, Vol 14 (2020) |
| ISSN: | 1662-453X 1662-4548 |
| Popis: | In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been highlighted as a key cellular mechanism to reduce the side effects of KOPr agonists. The present study investigated KOPr signaling bias and the acute antinociceptive effects and side effects of two novel analogs of SalA, 16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias, whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious. 16-Ethynyl SalA and 16-Bromo SalA both had a longer duration of action in the warm water tail-withdrawal assay, and 16-Ethynyl had greater antinociceptive effect in the hot-plate assay, compared to SalA. In the intraplantar 2% formaldehyde test, 16-Ethynyl SalA and 16-Bromo SalA significantly reduced both nociceptive and inflammatory pain-related behaviors. Moreover, 16-Ethynyl SalA and 16-Bromo SalA had no anxiogenic effects in the marble burying task, and 16-Bromo SalA did not alter behavior in the elevated zero maze. Overall, 16-Ethynyl SalA significantly attenuated acute pain-related behaviors in multiple preclinical models, while the biased KOPr agonist, 16-Bromo SalA, displayed modest antinociceptive effects, and lacked anxiogenic effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|